![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessIntraoperative strategies and techniques to achieve surgical radicality in pancreatic cancer
The treatment of pancreatic cancer presents a challenging task in surgical oncology, demanding innovative approaches to achieve radical resection and improve patient outcomes. This article provides an overview...
-
Article
Open AccessSingle-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy
Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer mortality by 2030. Bulk transcriptomic analyses have distinguished ‘classical’ from ‘basal-like’ tumors with more a...
-
Article
Neoadjuvant and adjuvant chemotherapy in pancreatic cancer
Only 15–20% of patients with pancreatic ductal adenocarcinoma (PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment concepts including neoadjuvant chemotherapy are therefore n...